EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Long‐term child outcomes after prenatal aspirin exposure: A 4‐year follow‐up of a randomized controlled trial (the APRIL study)

Emilie V J van Limburg Stirum iD, Janneke van 't Hooft, Anadeijda J E M C Landman iD, Martijn J J Finken iD, Anita C J Ravelli iD, Aleid G Leemhuis iD, Eva Pajkrt iD, Martijn A Oudijk iD, Marjon A de Boer iD

International Journal of Gynecology & Obstetrics · 2025

DOI: 10.1002/ijgo.70581 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2025. Verfasst von Emilie V J van Limburg Stirum und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Aspirin, Prenatal Exposure Delayed Effects, Obstetric Labor, Premature. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Amsterdam Reproduction & Development Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify the long‐term child outcomes after prenatal aspirin exposure.

Methods

This study is a follow‐up of a randomized controlled trial (RCT) evaluating low‐dose aspirin in the prevention of recurrent spontaneous preterm labor (the APRIL study) comparing aspirin 80 mg daily ( n = 194) to placebo ( n = 193) in singletons. Children were assessed at 4 years corrected age using the Ages and Stages Questionnaire (third edition, ASQ‐3) and the Strengths and Difficulties Questionnaire (SDQ) for (neuro)development and behavioral outcomes, respectively. Data on mortality, general health, growth and a composite of abnormal child outcome or mortality were also collected. Analyses were performed reporting odds ratio (OR) and 95% confidence intervals (CIs).

Results

Eight children were deceased until 4 years follow‐up (all perinatal deaths; n = 6 in aspirin and n = 2 in the placebo group). We included 231/379 (60.9%) children: 111/231 in the aspirin and 120/231 in the placebo groups. Total ASQ‐3 score was higher in the aspirin group (mean 259.3 vs. 248.3, mean difference 10.96, 95% CI: 0.17–21.76). The rate of children with an ASQ‐3 score of ≥1SD below the normative data did not differ between groups (35.2% vs. 47.4%; OR 0.60, 95% CI: 0.33–1.09), nor did a score on the SDQ ≥80th centile (18.3% vs. 14.7%; OR 1.30, 95% CI: 0.64–2.66). General health, growth and the composite outcome of abnormal child development or mortality did not significantly differ between groups.

Conclusion

We found no harmful effects of daily prenatal exposure to aspirin 80 mg. Our findings contribute to the existing data confirming the safety of low‐dose aspirin use in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPrenatal Exposure Delayed EffectsObstetric Labor, PrematureHumansPregnancyFemaleFollow-Up StudiesChild, PreschoolAdultMaleChild DevelopmentInfant, Newborn

Stichwörter der Autor:innen

aspirinfollow‐uplong‐term healthpregnancysafety

Substanzen

Aspirin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands.
  • Department of Obstetrics and Gynecology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Department of Pediatric Endocrinology, Amsterdam UMC, Vrije Universiteit Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
  • Department of Medical Informatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Neonatology and Pediatrics, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.

ORCID-Profile: Emilie V J van Limburg Stirum, Anadeijda J E M C Landman, Martijn J J Finken, Anita C J Ravelli, Aleid G Leemhuis, Eva Pajkrt, Martijn A Oudijk, Marjon A de Boer

Förderung

  • the Amsterdam Reproduction & Development Research Institute

Zitieren

APA

van Limburg Stirum, E. V. J., van 't Hooft, J., Landman, A. J. E. M. C., Finken, M. J. J., Ravelli, A. C. J., Leemhuis, A. G., Pajkrt, E., Oudijk, M. A., & de Boer, M. A. (2025). Long‐term child outcomes after prenatal aspirin exposure: A 4‐year follow‐up of a randomized controlled trial (the APRIL study). International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70581

Vancouver

van Limburg Stirum EVJ, van 't Hooft J, Landman AJEMC, Finken MJJ, Ravelli ACJ, Leemhuis AG, et al. Long‐term child outcomes after prenatal aspirin exposure: A 4‐year follow‐up of a randomized controlled trial (the APRIL study). International Journal of Gynecology & Obstetrics. 2025. doi:10.1002/ijgo.70581

BibTeX
@article{vanLimburgStirum2025,
  author = {van Limburg Stirum, Emilie V J and van 't Hooft, Janneke and Landman, Anadeijda J E M C and Finken, Martijn J J and Ravelli, Anita C J and Leemhuis, Aleid G and Pajkrt, Eva and Oudijk, Martijn A and de Boer, Marjon A},
  title = {Long‐term child outcomes after prenatal aspirin exposure: A 4‐year follow‐up of a randomized controlled trial (the APRIL study)},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2025},
  doi = {10.1002/ijgo.70581}
}
Kostenlos starten →